ReleaseWire Connect

GBI Research, leading business intelligence provider, has released its latest research report, entitled “Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development". Over the last decade, protein and peptide-based therapeutics have attracted more and more attention in the pharmaceutical industry. These types of molecules exert a high level of specificity on their respective molecular targets, making them highly advantageous and allowing them to be exploited therapeutically.

GBI Research, leading business intelligence provider, has released its latest research report, entitled “Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities”. It provides a comprehensive overview of the healthcare system, and the pricing and reimbursement processes in the top seven countries of the world, with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major pharmaceutical changes and oncology-related pricing and reimbursement in these countries in the recent past and their impact in the near future. The countries analyzed in the report are the US, the top five European countries of the UK, France, Italy, Germany and Spain; and Japan.

GBI Research, the leading business intelligence provider, has released its latest research, “Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise”, which provides an overview of the discovery and development of therapeutic drug combinations and multi-target drugs for oncology. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an insight into different methods and techniques used to identify and design drugs that act upon multiple targets in the treatment of cancer. It also focuses on the design and development of combination therapies to address multiple targets in oncology and the challenges surrounding this.

"Polyurethane Global Market to 2016 - Growth of Rigid and Flexible Polyurethane Foams in Asia-Pacific to Drive Global Demand” is an in-depth report from GBI Research which is focused on the demand side of the global polyurethane industry. The report provides the reader with detailed analysis and forecasts of the major economic and market trends affecting global polyurethane demand in the major regions of the world. It also provides analysis and description of the major drivers and restraints affecting polyurethane demand in various regions. Global polyurethane demand is assessed in terms of end-user segments and price and a competitive landscape, at both regional and country level. Overall, the report presents a comprehensive analysis of the global polyurethane market covering all the major parameters.

GBI Research, the leading business intelligence provider, has released its latest research, “Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline” which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

GBI Research’s report, “Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Majority of the Manufacturing Activity” provides detailed insight into the Europe API market. The research presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region. The report contains market forecasts, product type analysis, drivers and restraints. In addition, it includes market forecasts, product type analysis, therapeutic categories analysis and CMO growth in the region and its influence on API manufacturing activity towards 2017. Overall, the report presents a comprehensive analysis of the Europe API market, covering all the major parameters.

GBI Research, a leading business intelligence provider, has released its latest research, “Emerging Power Markets in South-East Asia, Middle East and Africa to 2020 - Government’s Restructuring Reforms Encouraging Private Participation will Enhance Price Competition and Efficiency”. The report gives an in-depth analysis of power markets in seven of South-East Asia, Middle East and African countries, with forecasts through 2020. The research analyzes the regulatory framework and infrastructure of the countries’ respective power sector and provides a detailed forecast of power installed capacity and generation by all types of resources in each market to 2020.

GBI Research, the leading business intelligence provider, has released its latest report, “Biobanks - 2012 Year Book”. It provides key data, information and analysis of 37 of the world’s major biobanks. The report provides information on population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks. It also provides comprehensive analysis of funding, harmonization, the cost of biobanking, and partnership structure. In addition, the report reviews the factors determining the success and failure of biobanks.

GBI Research, the leading business intelligence provider, has released its latest research on, “Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings”, which provides insights into the impact of biobetter therapies on the top selling biologic therapeutics, the regulatory procedure surrounding entry in the biobetters market and including recent technological advances that have driven advancement in the market. The report provides an in-depth analysis of top selling biobetter products covering top selling protein classes, erythropoietin’s, granulocyte-colony stimulating factors (G-CSF), interferon-?, interferon-beta, insulin and insulin analogs, monoclonal antibodies (mAbs) and tumor Necrosis Factor-? (TNF-?). The report also includes insights into the biobetter therapeutics R&D pipeline. It analyzes the competitive landscape, including Mergers and Acquisitions (M&As), and licensing and co-development deals.

This report is the result of ICD Research / Strategic Defence Intelligence’s extensive market and company research covering the global military aviation MRO industry. It provides detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of the leading companies in the industry, and key news.